Pharmaceutical - Diabetes, Novartis

Filter

Current filters:

DiabetesNovartis

Popular Filters

Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

23-05-2013

Results of the INTERVAL study were published on line in The Lancet today (May 23) and for the first time…

DiabetesGalvusNovartisPharmaceuticalResearch

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero

22-01-2013

Following positive recommendations from the European Medicines Agency's advisory committee, the European…

BexseroDiabetesEuropeNovartisNovo NordiskPharmaceuticalRegulationRyzodegTresibaVaccines

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV

06-09-2012

New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…

DiabetesLucentisNovartisOphthalmicsPharmaceuticalRegulationResearchRoche

Drug approval and launch for Novartis in China, where Quintiles expands

18-01-2012

Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

Mixed NICE recommendations for CML and diabetes drugs

13-01-2012

In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

Novartis to drop Rasilez/Tekturna in high-risk patients with diabetes and renal impairment

21-12-2011

In a major disappointment for Swiss drug major Novartis (NOVN: VX), the company says that, following…

Cardio-vascularDiabetesMarkets & MarketingNovartisPharmaceuticalRasilezResearchTekturna

Diabetes Rxing in China and S Korea

07-12-2011

Dipeptidyl peptidase IV (DPP-IV) inhibitors are prescribed more commonly for the treatment of type 2…

Asia-PacificDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisPharmaceuticalPricing

EU approval for added use of Novartis diabetes drug Galvus

06-12-2011

The European Commission has approved Swiss drug major Novartis’ (NOVN: VX) Galvus (vildagliptin)…

DiabetesEuropeGalvusNovartisPharmaceuticalRegulation

Company Spotlight

ImmunoGen

ImmunoGen

Back to top